Download PDF
Zentralbl Chir 2014; 139(06): 569-571
DOI: 10.1055/s-0034-1398701
Aktuelle Chirurgie
Georg Thieme Verlag KG Stuttgart · New York

Krebstherapie – Neue Aspekte zur neoadjuvanten Therapie bei Malignomen des oberen GITs

Stefan P. Mönig
,
Felix Berth
,
Seung-Hun Chon
Further Information

Publication History

Publication Date:
22 December 2014 (online)

Also available at
    Permissions and Reprints

Die Bedeutung der mulitmodalen Krebstherapie nimmt stetig zu und der Einfluss neoadjuvanter Methoden auf den Behandlungserfolg wird intensiv erforscht. Eine Vielzahl aktueller Studien beeinflusst die Therapieempfehlungen zur Behandlung maligner Tumoren im oberen Gastrointestinaltrakt.

 

  • Literatur

  • 1 Moehler M, Al-Batran SE et al. German S3-guideline „Diagnosis and treatment of esophagogastric cancer“. Z Gastroenterol 2011; 49: 461-531
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Mönig SP, Meyer HJ, Allum WH et al. Third international conference of the European Union Network of Excellence on gastric and esophagogastric cancer, Cologne, Germany, June 2012. Gastric Cancer 2014; [Epub ahead of print]
    PubMedGoogle Scholar
  • 3 Messager M, Lefevre JH, Pichot-Delahaye V et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011; 254: 684-693
    CrossrefPubMedGoogle Scholar
  • 4 Heger U, Blank S, Wiecha C et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?. Ann Surg Oncol 2014; 21: 1739-1748
    CrossrefPubMedGoogle Scholar
  • 5 Meyer HJ, Hölscher AH et al. Current S3 guidelines on surgical treatment of gastric carcinoma. Chirurg 2012; 83: 31-37
    CrossrefPubMedGoogle Scholar
  • 6 Lordick F, Hölscher AH, Haustermans K et al. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013; 398: 177-187
    CrossrefPubMedGoogle Scholar
  • 7 Sjoquist KM, Burmeister BH, Smithers BM. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692
    CrossrefPubMedGoogle Scholar
  • 8 van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
    CrossrefPubMedGoogle Scholar
  • 9 van Heijl M, van Lanschot JJ, Koppert LB et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus [CROSS]. BMC Surg 2008; 8: 21
    CrossrefPubMedGoogle Scholar
  • 10 Thuss-Patience P, Kutup A, Eble M. Adenokarzinome des Magens und gastroösophagealen Übergangs – Neoadjuvante und adjuvante Therapie. Der Onkologe 2013; 5: 371-379
    PubMedGoogle Scholar
  • 11 Allum WH, Stenning SP, Bancewicz J et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067
    CrossrefPubMedGoogle Scholar
  • 12 Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721
    CrossrefPubMedGoogle Scholar
  • 13 Schumacher C, Gretschl S, Lordick F et al. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin Oncol 2010; 28: 5210-5218
    CrossrefPubMedGoogle Scholar
  • 14 Piessen G, Messager M, Leteurtre E et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009; 250: 878-887
    CrossrefPubMedGoogle Scholar
  • 15 Piessen G, Messager M, Le Malicot K et al. Phase II / III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002. BMC Cancer 2013; 13: 281
    CrossrefPubMedGoogle Scholar
  • 16 Mönig SP, Zirbes TK, Schröder W et al. Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol 1999; 173: 365-367
    CrossrefPubMedGoogle Scholar
  • 17 Mönig SP, Schröder W, Baldus SE et al. Preoperative lymph-node staging in gastrointestinal cancer-correlation between size and tumor stage. Onkologie 2002; 25: 342-344
    CrossrefPubMedGoogle Scholar
  • 18 Ruol A, Rizzetto C, Castoro C et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?. Ann Surg 2010; 252: 788-796
    CrossrefPubMedGoogle Scholar
  • 19 Kim JY, Correa AM, Vaporciyan AA et al. Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome?. Ann Thorac Surg 2012; 93: 207-212
    CrossrefPubMedGoogle Scholar
  • 20 Chiu CH, Chao YK, Chang HK et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?. Ann Surg Oncol 2013; 20: 4245-4251
    CrossrefPubMedGoogle Scholar
  • 21 Martin LW. What is the optimal interval between chemoradiation and esophagectomy?. Semin Thorac Cardiovasc Surg 2012; 24: 87-89
    CrossrefPubMedGoogle Scholar